Please login to the form below

Not currently logged in
Email:
Password:

liver cancer

This page shows the latest liver cancer news and features for those working in and with pharma, biotech and healthcare.

CRUK forges £30m ‘post-Brexit’ R&D alliance

CRUK forges £30m ‘post-Brexit’ R&D alliance

One UK project – called HUNTER - is getting £5m to look into immunotherapies for liver cancer and will be led by Newcastle University. ... It aims to develop a network of EU and UK clinicians and scientists specialising in hepatocellular carcinoma (HCC

Latest news

  • Eisai’s Lenvima wins European liver cancer indication Eisai’s Lenvima wins European liver cancer indication

    Eisai’ s Lenvima wins European liver cancer indication. EC green-lights the RTK inhibitor as a first-line treatment. ... cancer. It is now set as a first-line treatment for adults who have received no prior systemic therapy for advanced or unresectable

  • ACT immunotherapy cures terminal breast cancer patient ACT immunotherapy cures terminal breast cancer patient

    Judy Perkins had hormone receptor-positive breast cancer that had spread to her liver and other organs and had exhausted all other treatment options, including several rounds of chemotherapy, and none ... The new study suggests that barrier could be

  • $5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima $5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

    submitted for approval for hepatocellular carcinoma, a form of liver cancer. ... A second cohort of endometrial cancer patients had an ORR of 52% at the same timepoint.

  • BMS gets OK for monthly Opdivo dosing BMS gets OK for monthly Opdivo dosing

    cancer. It is competing in the marketplace with two other PD-1 inhibitors - Merck &Co/MSD’s Keytruda (pembrolizumab) and Roche’s Tecentriq (atezolizumab) - as well as PD-L1 inhibitors Imfinzi ... The new monthly injection can be used in a range of

  • Gilead adds to CAR-T assets with Cell Design Labs buyout Gilead adds to CAR-T assets with Cell Design Labs buyout

    The company’s programmes are still in preclinical development and include projects in prostate cancer, liver cancer and multiple myeloma. ... It’s an exciting time, ”said Renier Brentjens, medical oncologist and director of cellular therapeutics at

More from news
Approximately 10 fully matching, plus 106 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... Other oncolytic viruses are coming through the pipeline, including SillaJen/Transgene’s Pexa-Vec for liver cancer and other solid

  • Accelerating innovation Accelerating innovation

    Much like its work in liver cancer with Cabometyx, being active in pancreatic cancer allows it to compete in less crowded areas, a tacit acknowledgement that, for now, it lacks the ... We try to [focus on] pancreas, liver and bladder cancer, where there

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Co-development was another area in which major pharma firms were active, particularly Lilly, which enlarged its work with Boehringer Ingelheim to add in breast cancer programmes and closed a ... NASH and biosimilars. One therapeutic indication that could

  • Pharma deals in April 2015 Pharma deals in April 2015

    The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid. ... Menarini AP will be responsible for the clinical development, regulatory approval and commercialisation of resminostat in all oncological

  • Pharma deals during September 2013 Pharma deals during September 2013

    The lead pipeline candidates are SGI-110, a subcutaneous hypomethylating agent in multiple studies for a variety of haematological and solid tumour oncology indications, including MDS, AML, ovarian cancer and liver ... cancer, and AT13387, a second

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • 90TEN nominated for five Communiqué Awards

    Meanwhile two of the agency’ s campaigns for Sirtex - in collaboration with Denovo Strategy - in metastatic colorectal liver cancer are shortlisted, for Excellence in Media Relations and Excellence in Integrated

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics